医护人员 COVID-19 疫苗的早期安全性监测。
Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers.
机构信息
Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
Department of Hospital Infection Control, Korea University Guro Hospital, Seoul, Korea.
出版信息
J Korean Med Sci. 2021 Apr 19;36(15):e110. doi: 10.3346/jkms.2021.36.e110.
Abstract
Hospital-based surveillance for adverse events was conducted on healthcare workers after they received the first dose of coronavirus disease 2019 (COVID-19) vaccine. Among the two new platform vaccines (messenger RNA- and adenoviral vector-based vaccines), the rates of systemic adverse events were significantly higher among adenovirus-vectored vaccine recipients. Fatigue (87.6% vs. 53.8%), myalgia (80.8% vs. 50.0%), headache (72.0% vs. 28.8%), and fever (≥ 38.0°C, 38.7% vs. 0%) were the most common adverse events among adenovirus-vectored vaccine recipients, but most symptoms resolved within 2 days. Both types of COVID-19 vaccines were generally safe, and serious adverse events rarely occurred.
摘要
在医护人员接种首剂 2019 冠状病毒病（COVID-19）疫苗后，对他们进行了基于医院的不良事件监测。在两种新平台疫苗（信使 RNA 和腺病毒载体疫苗）中，腺病毒载体疫苗接种者的全身性不良事件发生率显著更高。腺病毒载体疫苗接种者中最常见的不良事件包括疲劳（87.6%比 53.8%）、肌痛（80.8%比 50.0%）、头痛（72.0%比 28.8%）和发热（≥38.0°C，38.7%比 0%），但大多数症状在 2 天内得到缓解。两种 COVID-19 疫苗总体上均安全，且很少发生严重不良事件。
相似文献
1
Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers.医护人员 COVID-19 疫苗的早期安全性监测。
J Korean Med Sci. 2021 Apr 19;36(15):e110. doi: 10.3346/jkms.2021.36.e110.
2
Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea.韩国医护人员中第二剂 BNT162b2 mRNA COVID-19 疫苗的不良反应。
J Korean Med Sci. 2021 May 31;36(21):e153. doi: 10.3346/jkms.2021.36.e153.
3
Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.75 岁及以上成年人接种 BNT162b2 新冠疫苗后的安全性监测。
J Korean Med Sci. 2021 Nov 22;36(45):e318. doi: 10.3346/jkms.2021.36.e318.
4
Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.疫苗不良事件自动报告系统中报告的与 2019 年冠状病毒病疫苗接种相关的不良事件。
J Korean Med Sci. 2021 May 3;36(17):e114. doi: 10.3346/jkms.2021.36.e114.
5
Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.韩国医护人员接种 ChAdOx1 nCoV-19 疫苗和 BNT162b2 疫苗第一针后的不良反应。
J Korean Med Sci. 2021 May 3;36(17):e115. doi: 10.3346/jkms.2021.36.e115.
6
Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.医护人员接种 ChAdOx1 nCoV-19 或 BNT162b2 mRNA COVID-19 疫苗第一针后出现的不良事件：单中心经验。
J Korean Med Sci. 2021 Apr 12;36(14):e107. doi: 10.3346/jkms.2021.36.e107.
7
COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says.COVID-19 mRNA 疫苗在短期内通常是安全的：一项疫苗监测真实世界研究称。
Front Immunol. 2021 May 21;12:669010. doi: 10.3389/fimmu.2021.669010. eCollection 2021.
8
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
9
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.基于复制缺陷型猴腺病毒载体 ChAdOx1 的疫苗：风险/收益评估的关键考虑因素标准化模板。
Vaccine. 2022 Aug 19;40(35):5248-5262. doi: 10.1016/j.vaccine.2022.06.008. Epub 2022 Jun 14.
10
Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran.伊朗比尔詹德市医护人员中新冠病毒疫苗（卫星五号、阿斯利康新冠疫苗和科瓦克辛）副作用的发生率
Int Immunopharmacol. 2021 Dec;101(Pt B):108351. doi: 10.1016/j.intimp.2021.108351. Epub 2021 Nov 10.
引用本文的文献
1
Central nervous system manifestations following vaccination against COVID-19.接种新型冠状病毒疫苗后的中枢神经系统表现。
Brain Behav Immun Health. 2024 May 3;38:100788. doi: 10.1016/j.bbih.2024.100788. eCollection 2024 Jul.
2
Severity of Adverse Effects of Sinovac COVID-19 Vaccine in Postmenopausal Women: A Multicenter Experience From Pakistan.科兴新冠疫苗在绝经后女性中的不良反应严重程度：来自巴基斯坦的多中心经验
Cureus. 2023 Oct 8;15(10):e46682. doi: 10.7759/cureus.46682. eCollection 2023 Oct.
3
Herpes zoster after COVID-19 vaccination, aspect of pain medicine: a retrospective, single-center study.新冠疫苗接种后带状疱疹的疼痛医学方面：一项回顾性单中心研究
Anesth Pain Med (Seoul). 2023 Jan;18(1):57-64. doi: 10.17085/apm.22207. Epub 2023 Jan 16.
4
Psychological Distress and Physical Adverse Events of COVID-19 Vaccination among Healthcare Workers in Taiwan.台湾医护人员接种新冠疫苗后的心理困扰与身体不良事件
Vaccines (Basel). 2023 Jan 5;11(1):129. doi: 10.3390/vaccines11010129.
5
A systemic review and recommendation for an autopsy approach to death followed the COVID 19 vaccination.一项针对 COVID-19 疫苗接种后死亡的尸检方法的系统回顾和建议。
Forensic Sci Int. 2022 Nov;340:111469. doi: 10.1016/j.forsciint.2022.111469. Epub 2022 Sep 20.
6
Prevalence of COVID-19 vaccine reactogenicity among Bangladeshi physicians.孟加拉国医生中新冠疫苗反应原性的流行情况。
FASEB Bioadv. 2022 Mar 24;4(6):379-390. doi: 10.1096/fba.2021-00158. eCollection 2022 Jun.
7
Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis.全球2019冠状病毒病疫苗的安全性：一项荟萃分析
Vaccines (Basel). 2022 Apr 12;10(4):596. doi: 10.3390/vaccines10040596.
8
Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis.接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗后头痛发作：一项系统文献综述和荟萃分析
J Headache Pain. 2022 Mar 31;23(1):41. doi: 10.1186/s10194-022-01400-4.
9
Adverse events following the first dose of Covishield (ChAdOx1 nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study.尼泊尔中部和西部地区选定地区卫生工作者接种 Covishield（ChAdOx1 nCoV-19）疫苗第一针后的不良事件：一项横断面研究。
PLoS One. 2021 Dec 21;16(12):e0260638. doi: 10.1371/journal.pone.0260638. eCollection 2021.
10
Sex and Gender in COVID-19 Vaccine Research: Substantial Evidence Gaps Remain.新冠疫苗研究中的性别与性：重大证据空白依然存在。
Front Glob Womens Health. 2021 Nov 1;2:761511. doi: 10.3389/fgwh.2021.761511. eCollection 2021.
本文引用的文献
1
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
2
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
3
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.在年轻和老年成年人中进行的一次单盲、随机、对照、2/3 期试验中，观察 ChAdOx1 nCoV-19 疫苗在初免-加强免疫方案中的安全性和免疫原性（COV002）。
Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19.
Zotero 插件